Google
×
Past year
  • Any time
  • Past hour
  • Past 24 hours
  • Past week
  • Past month
  • Past year
All results
Jun 24, 2024 · Whatever the indication for DLI, mortality related to post-DLI infusion is 5%–20%, and more than one-third of patients will develop acute and/or chronic graft ...
Dec 18, 2023 · The GvL effect can be leveraged to re-introduce remission in some patients through strategies such as immunosuppression taper or donor lymphocyte infusion (DLI); ...
Missing: decides | Show results with:decides
Mar 4, 2024 · Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Missing: decides | Show results with:decides
Nov 11, 2023 · Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia ...
Missing: decides | Show results with:decides
Nov 17, 2023 · Chronic myelogenous leukemia treatment may include targeted therapy, immunotherapy, chemotherapy, stem cell transplant, donor lymphocyte infusion, ...
Nov 11, 2023 · Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia ...
Missing: decides | Show results with:decides
Nov 17, 2023 · The donor's lymphocytes are thawed if they were frozen and then given to the patient through one or more infusions. The lymphocytes see the patient's cancer ...
Missing: decides outcome.
Jan 4, 2024 · Most patients with acute myeloid leukemia (AML) develop refractory/relapsed (R/R) disease even in the presence of novel and targeted therapies.
Missing: chronic decides
Apr 11, 2024 · Donor lymphocyte infusions (DLIs) are an established cellular strategy for preventing AML relapse following allo-SCT, and are commonly administered ...
Missing: decides | Show results with:decides
Aug 29, 2024 · A higher count of CD4 + T cell on “day 90” after HSCT was the single predictor of a lower fatality risk across all lymphocyte subgroups.
Missing: myelogenous dose decides